A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Exclusion Criteria

• •Pregnancy or breastfeeding
• •Severe renal impairment or the need for dialysis or renal transplantation
• •Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
• •Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation
• •Known active infection of any kind or recent major episode of infection
• •Intolerance or contraindication to study therapies